Industry Research Reports

Home > Reports > Chemical & Material > Tocilizumab- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Tocilizumab- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Industry: Chemical & Material

Published Date: 2025-02-15

Pages: 115 Pages

Report ld: 3958261

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global market for Tocilizumab was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.

Tocilizumab is a humanized monoclonal antibody resistant against the interleukin-6 receptor (IL-6R). It is an immunosuppressive agent commonly used for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis.

North American market for Tocilizumab was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Tocilizumab was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Tocilizumab was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global key companies of Tocilizumab include Bio-Rad Laboratories, Bio-Techne, BioVision, Selleck Chemicals, Biorbyt, AbMole, Biosynth Carbosynth, SimSon Pharma, BOC Sciences, Clearsynth, etc. In 2024, the global five largest players hold a share approximately % in terms of revenue.

This report aims to provide a comprehensive presentation of the global market for Tocilizumab, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Tocilizumab by region & country, by Type, and by Application.

The Tocilizumab market size, estimations, and forecasts are provided in terms of sales volume (Kg) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tocilizumab.

MARKET SEGMENTATION

By Company

Bio-Rad Laboratories
Bio-Techne
BioVision
Selleck Chemicals
Biorbyt
AbMole
Biosynth Carbosynth
SimSon Pharma
BOC Sciences
Clearsynth
LifeSpan BioSciences

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Min Purity Less Than 98%
Min Purity 98%-99%
Min Purity More Than 99%

Segment by Application

Research
Medical

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Tocilizumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Tocilizumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Tocilizumab in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Tocilizumab Product Introduction

1.2 Global Tocilizumab Market Size Forecast

1.2.1 Global Tocilizumab Sales Value (2020-2031)

1.2.2 Global Tocilizumab Sales Volume (2020-2031)

1.2.3 Global Tocilizumab Sales Price (2020-2031)

1.3 Tocilizumab Market Trends & Drivers

1.3.1 Tocilizumab Industry Trends

1.3.2 Tocilizumab Market Drivers & Opportunity

1.3.3 Tocilizumab Market Challenges

1.3.4 Tocilizumab Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Tocilizumab Players Revenue Ranking (2024)

2.2 Global Tocilizumab Revenue by Company (2020-2025)

2.3 Global Tocilizumab Players Sales Volume Ranking (2024)

2.4 Global Tocilizumab Sales Volume by Company Players (2020-2025)

2.5 Global Tocilizumab Average Price by Company (2020-2025)

2.6 Key Manufacturers Tocilizumab Manufacturing Base and Headquarters

2.7 Key Manufacturers Tocilizumab Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Tocilizumab

2.9 Tocilizumab Market Competitive Analysis

2.9.1 Tocilizumab Market Concentration Rate (2020-2025)

2.9.2 Global 5 and 10 Largest Manufacturers by Tocilizumab Revenue in 2024

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tocilizumab as of 2024)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Min Purity Less Than 98%

3.1.2 Min Purity 98%-99%

3.1.3 Min Purity More Than 99%

3.2 Global Tocilizumab Sales Value by Type

3.2.1 Global Tocilizumab Sales Value by Type (2020 VS 2024 VS 2031)

3.2.2 Global Tocilizumab Sales Value, by Type (2020-2031)

3.2.3 Global Tocilizumab Sales Value, by Type (%) (2020-2031)

3.3 Global Tocilizumab Sales Volume by Type

3.3.1 Global Tocilizumab Sales Volume by Type (2020 VS 2024 VS 2031)

3.3.2 Global Tocilizumab Sales Volume, by Type (2020-2031)

3.3.3 Global Tocilizumab Sales Volume, by Type (%) (2020-2031)

3.4 Global Tocilizumab Average Price by Type (2020-2031)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Research

4.1.2 Medical

4.2 Global Tocilizumab Sales Value by Application

4.2.1 Global Tocilizumab Sales Value by Application (2020 VS 2024 VS 2031)

4.2.2 Global Tocilizumab Sales Value, by Application (2020-2031)

4.2.3 Global Tocilizumab Sales Value, by Application (%) (2020-2031)

4.3 Global Tocilizumab Sales Volume by Application

4.3.1 Global Tocilizumab Sales Volume by Application (2020 VS 2024 VS 2031)

4.3.2 Global Tocilizumab Sales Volume, by Application (2020-2031)

4.3.3 Global Tocilizumab Sales Volume, by Application (%) (2020-2031)

4.4 Global Tocilizumab Average Price by Application (2020-2031)

5 Segmentation by Region

5.1 Global Tocilizumab Sales Value by Region

5.1.1 Global Tocilizumab Sales Value by Region: 2020 VS 2024 VS 2031

5.1.2 Global Tocilizumab Sales Value by Region (2020-2025)

5.1.3 Global Tocilizumab Sales Value by Region (2026-2031)

5.1.4 Global Tocilizumab Sales Value by Region (%), (2020-2031)

5.2 Global Tocilizumab Sales Volume by Region

5.2.1 Global Tocilizumab Sales Volume by Region: 2020 VS 2024 VS 2031

5.2.2 Global Tocilizumab Sales Volume by Region (2020-2025)

5.2.3 Global Tocilizumab Sales Volume by Region (2026-2031)

5.2.4 Global Tocilizumab Sales Volume by Region (%), (2020-2031)

5.3 Global Tocilizumab Average Price by Region (2020-2031)

5.4 North America

5.4.1 North America Tocilizumab Sales Value, 2020-2031

5.4.2 North America Tocilizumab Sales Value by Country (%), 2024 VS 2031

5.5 Europe

5.5.1 Europe Tocilizumab Sales Value, 2020-2031

5.5.2 Europe Tocilizumab Sales Value by Country (%), 2024 VS 2031

5.6 Asia Pacific

5.6.1 Asia Pacific Tocilizumab Sales Value, 2020-2031

5.6.2 Asia Pacific Tocilizumab Sales Value by Region (%), 2024 VS 2031

5.7 South America

5.7.1 South America Tocilizumab Sales Value, 2020-2031

5.7.2 South America Tocilizumab Sales Value by Country (%), 2024 VS 2031

5.8 Middle East & Africa

5.8.1 Middle East & Africa Tocilizumab Sales Value, 2020-2031

5.8.2 Middle East & Africa Tocilizumab Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Tocilizumab Sales Value Growth Trends, 2020 VS 2024 VS 2031

6.2 Key Countries/Regions Tocilizumab Sales Value

6.2.1 Key Countries/Regions Tocilizumab Sales Value, 2020-2031

6.2.2 Key Countries/Regions Tocilizumab Sales Volume, 2020-2031

6.3 United States

6.3.1 United States Tocilizumab Sales Value, 2020-2031

6.3.2 United States Tocilizumab Sales Value by Type (%), 2024 VS 2031

6.3.3 United States Tocilizumab Sales Value by Application, 2024 VS 2031

6.4 Europe

6.4.1 Europe Tocilizumab Sales Value, 2020-2031

6.4.2 Europe Tocilizumab Sales Value by Type (%), 2024 VS 2031

6.4.3 Europe Tocilizumab Sales Value by Application, 2024 VS 2031

6.5 China

6.5.1 China Tocilizumab Sales Value, 2020-2031

6.5.2 China Tocilizumab Sales Value by Type (%), 2024 VS 2031

6.5.3 China Tocilizumab Sales Value by Application, 2024 VS 2031

6.6 Japan

6.6.1 Japan Tocilizumab Sales Value, 2020-2031

6.6.2 Japan Tocilizumab Sales Value by Type (%), 2024 VS 2031

6.6.3 Japan Tocilizumab Sales Value by Application, 2024 VS 2031

6.7 South Korea

6.7.1 South Korea Tocilizumab Sales Value, 2020-2031

6.7.2 South Korea Tocilizumab Sales Value by Type (%), 2024 VS 2031

6.7.3 South Korea Tocilizumab Sales Value by Application, 2024 VS 2031

6.8 Southeast Asia

6.8.1 Southeast Asia Tocilizumab Sales Value, 2020-2031

6.8.2 Southeast Asia Tocilizumab Sales Value by Type (%), 2024 VS 2031

6.8.3 Southeast Asia Tocilizumab Sales Value by Application, 2024 VS 2031

6.9 India

6.9.1 India Tocilizumab Sales Value, 2020-2031

6.9.2 India Tocilizumab Sales Value by Type (%), 2024 VS 2031

6.9.3 India Tocilizumab Sales Value by Application, 2024 VS 2031

7 Company Profiles

7.1 Bio-Rad Laboratories

7.1.1 Bio-Rad Laboratories Company Information

7.1.2 Bio-Rad Laboratories Introduction and Business Overview

7.1.3 Bio-Rad Laboratories Tocilizumab Sales, Revenue, Price and Gross Margin (2020-2025)

7.1.4 Bio-Rad Laboratories Tocilizumab Product Offerings

7.1.5 Bio-Rad Laboratories Recent Development

7.2 Bio-Techne

7.2.1 Bio-Techne Company Information

7.2.2 Bio-Techne Introduction and Business Overview

7.2.3 Bio-Techne Tocilizumab Sales, Revenue, Price and Gross Margin (2020-2025)

7.2.4 Bio-Techne Tocilizumab Product Offerings

7.2.5 Bio-Techne Recent Development

7.3 BioVision

7.3.1 BioVision Company Information

7.3.2 BioVision Introduction and Business Overview

7.3.3 BioVision Tocilizumab Sales, Revenue, Price and Gross Margin (2020-2025)

7.3.4 BioVision Tocilizumab Product Offerings

7.3.5 BioVision Recent Development

7.4 Selleck Chemicals

7.4.1 Selleck Chemicals Company Information

7.4.2 Selleck Chemicals Introduction and Business Overview

7.4.3 Selleck Chemicals Tocilizumab Sales, Revenue, Price and Gross Margin (2020-2025)

7.4.4 Selleck Chemicals Tocilizumab Product Offerings

7.4.5 Selleck Chemicals Recent Development

7.5 Biorbyt

7.5.1 Biorbyt Company Information

7.5.2 Biorbyt Introduction and Business Overview

7.5.3 Biorbyt Tocilizumab Sales, Revenue, Price and Gross Margin (2020-2025)

7.5.4 Biorbyt Tocilizumab Product Offerings

7.5.5 Biorbyt Recent Development

7.6 AbMole

7.6.1 AbMole Company Information

7.6.2 AbMole Introduction and Business Overview

7.6.3 AbMole Tocilizumab Sales, Revenue, Price and Gross Margin (2020-2025)

7.6.4 AbMole Tocilizumab Product Offerings

7.6.5 AbMole Recent Development

7.7 Biosynth Carbosynth

7.7.1 Biosynth Carbosynth Company Information

7.7.2 Biosynth Carbosynth Introduction and Business Overview

7.7.3 Biosynth Carbosynth Tocilizumab Sales, Revenue, Price and Gross Margin (2020-2025)

7.7.4 Biosynth Carbosynth Tocilizumab Product Offerings

7.7.5 Biosynth Carbosynth Recent Development

7.8 SimSon Pharma

7.8.1 SimSon Pharma Company Information

7.8.2 SimSon Pharma Introduction and Business Overview

7.8.3 SimSon Pharma Tocilizumab Sales, Revenue, Price and Gross Margin (2020-2025)

7.8.4 SimSon Pharma Tocilizumab Product Offerings

7.8.5 SimSon Pharma Recent Development

7.9 BOC Sciences

7.9.1 BOC Sciences Company Information

7.9.2 BOC Sciences Introduction and Business Overview

7.9.3 BOC Sciences Tocilizumab Sales, Revenue, Price and Gross Margin (2020-2025)

7.9.4 BOC Sciences Tocilizumab Product Offerings

7.9.5 BOC Sciences Recent Development

7.10 Clearsynth

7.10.1 Clearsynth Company Information

7.10.2 Clearsynth Introduction and Business Overview

7.10.3 Clearsynth Tocilizumab Sales, Revenue, Price and Gross Margin (2020-2025)

7.10.4 Clearsynth Tocilizumab Product Offerings

7.10.5 Clearsynth Recent Development

7.11 LifeSpan BioSciences

7.11.1 LifeSpan BioSciences Company Information

7.11.2 LifeSpan BioSciences Introduction and Business Overview

7.11.3 LifeSpan BioSciences Tocilizumab Sales, Revenue, Price and Gross Margin (2020-2025)

7.11.4 LifeSpan BioSciences Tocilizumab Product Offerings

7.11.5 LifeSpan BioSciences Recent Development

8 Industry Chain Analysis

8.1 Tocilizumab Industrial Chain

8.2 Tocilizumab Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Tocilizumab Sales Model

8.5.2 Sales Channel

8.5.3 Tocilizumab Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Tocilizumab Market Trends

Table 2. Tocilizumab Market Drivers & Opportunity

Table 3. Tocilizumab Market Challenges

Table 4. Tocilizumab Market Restraints

Table 5. Global Tocilizumab Revenue by Company (2020-2025) & (US$ Million)

Table 6. Global Tocilizumab Revenue Market Share by Company (2020-2025)

Table 7. Global Tocilizumab Sales Volume by Company (2020-2025) & (Kg)

Table 8. Global Tocilizumab Sales Volume Market Share by Company (2020-2025)

Table 9. Global Market Tocilizumab Price by Company (2020-2025) & (K USD/Kg)

Table 10. Key Manufacturers Tocilizumab Manufacturing Base and Headquarters

Table 11. Key Manufacturers Tocilizumab Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Tocilizumab

Table 13. Global Tocilizumab Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tocilizumab as of 2024)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Tocilizumab Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)

Table 17. Global Tocilizumab Sales Value by Type (2020-2025) & (US$ Million)

Table 18. Global Tocilizumab Sales Value by Type (2026-2031) & (US$ Million)

Table 19. Global Tocilizumab Sales Market Share in Value by Type (2020-2025)

Table 20. Global Tocilizumab Sales Market Share in Value by Type (2026-2031)

Table 21. Global Tocilizumab Sales Volume by Type: 2020 VS 2024 VS 2031 (Kg)

Table 22. Global Tocilizumab Sales Volume by Type (2020-2025) & (Kg)

Table 23. Global Tocilizumab Sales Volume by Type (2026-2031) & (Kg)

Table 24. Global Tocilizumab Sales Market Share in Volume by Type (2020-2025)

Table 25. Global Tocilizumab Sales Market Share in Volume by Type (2026-2031)

Table 26. Global Tocilizumab Price by Type (2020-2025) & (K USD/Kg)

Table 27. Global Tocilizumab Price by Type (2026-2031) & (K USD/Kg)

Table 28. Global Tocilizumab Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)

Table 29. Global Tocilizumab Sales Value by Application (2020-2025) & (US$ Million)

Table 30. Global Tocilizumab Sales Value by Application (2026-2031) & (US$ Million)

Table 31. Global Tocilizumab Sales Market Share in Value by Application (2020-2025)

Table 32. Global Tocilizumab Sales Market Share in Value by Application (2026-2031)

Table 33. Global Tocilizumab Sales Volume by Application: 2020 VS 2024 VS 2031 (Kg)

Table 34. Global Tocilizumab Sales Volume by Application (2020-2025) & (Kg)

Table 35. Global Tocilizumab Sales Volume by Application (2026-2031) & (Kg)

Table 36. Global Tocilizumab Sales Market Share in Volume by Application (2020-2025)

Table 37. Global Tocilizumab Sales Market Share in Volume by Application (2026-2031)

Table 38. Global Tocilizumab Price by Application (2020-2025) & (K USD/Kg)

Table 39. Global Tocilizumab Price by Application (2026-2031) & (K USD/Kg)

Table 40. Global Tocilizumab Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)

Table 41. Global Tocilizumab Sales Value by Region (2020-2025) & (US$ Million)

Table 42. Global Tocilizumab Sales Value by Region (2026-2031) & (US$ Million)

Table 43. Global Tocilizumab Sales Value by Region (2020-2025) & (%)

Table 44. Global Tocilizumab Sales Value by Region (2026-2031) & (%)

Table 45. Global Tocilizumab Sales Volume by Region (Kg): 2020 VS 2024 VS 2031

Table 46. Global Tocilizumab Sales Volume by Region (2020-2025) & (Kg)

Table 47. Global Tocilizumab Sales Volume by Region (2026-2031) & (Kg)

Table 48. Global Tocilizumab Sales Volume by Region (2020-2025) & (%)

Table 49. Global Tocilizumab Sales Volume by Region (2026-2031) & (%)

Table 50. Global Tocilizumab Average Price by Region (2020-2025) & (K USD/Kg)

Table 51. Global Tocilizumab Average Price by Region (2026-2031) & (K USD/Kg)

Table 52. Key Countries/Regions Tocilizumab Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031

Table 53. Key Countries/Regions Tocilizumab Sales Value, (2020-2025) & (US$ Million)

Table 54. Key Countries/Regions Tocilizumab Sales Value, (2026-2031) & (US$ Million)

Table 55. Key Countries/Regions Tocilizumab Sales Volume, (2020-2025) & (Kg)

Table 56. Key Countries/Regions Tocilizumab Sales Volume, (2026-2031) & (Kg)

Table 57. Bio-Rad Laboratories Company Information

Table 58. Bio-Rad Laboratories Introduction and Business Overview

Table 59. Bio-Rad Laboratories Tocilizumab Sales (Kg), Revenue (US$ Million), Price (K USD/Kg) and Gross Margin (2020-2025)

Table 60. Bio-Rad Laboratories Tocilizumab Product Offerings

Table 61. Bio-Rad Laboratories Recent Development

Table 62. Bio-Techne Company Information

Table 63. Bio-Techne Introduction and Business Overview

Table 64. Bio-Techne Tocilizumab Sales (Kg), Revenue (US$ Million), Price (K USD/Kg) and Gross Margin (2020-2025)

Table 65. Bio-Techne Tocilizumab Product Offerings

Table 66. Bio-Techne Recent Development

Table 67. BioVision Company Information

Table 68. BioVision Introduction and Business Overview

Table 69. BioVision Tocilizumab Sales (Kg), Revenue (US$ Million), Price (K USD/Kg) and Gross Margin (2020-2025)

Table 70. BioVision Tocilizumab Product Offerings

Table 71. BioVision Recent Development

Table 72. Selleck Chemicals Company Information

Table 73. Selleck Chemicals Introduction and Business Overview

Table 74. Selleck Chemicals Tocilizumab Sales (Kg), Revenue (US$ Million), Price (K USD/Kg) and Gross Margin (2020-2025)

Table 75. Selleck Chemicals Tocilizumab Product Offerings

Table 76. Selleck Chemicals Recent Development

Table 77. Biorbyt Company Information

Table 78. Biorbyt Introduction and Business Overview

Table 79. Biorbyt Tocilizumab Sales (Kg), Revenue (US$ Million), Price (K USD/Kg) and Gross Margin (2020-2025)

Table 80. Biorbyt Tocilizumab Product Offerings

Table 81. Biorbyt Recent Development

Table 82. AbMole Company Information

Table 83. AbMole Introduction and Business Overview

Table 84. AbMole Tocilizumab Sales (Kg), Revenue (US$ Million), Price (K USD/Kg) and Gross Margin (2020-2025)

Table 85. AbMole Tocilizumab Product Offerings

Table 86. AbMole Recent Development

Table 87. Biosynth Carbosynth Company Information

Table 88. Biosynth Carbosynth Introduction and Business Overview

Table 89. Biosynth Carbosynth Tocilizumab Sales (Kg), Revenue (US$ Million), Price (K USD/Kg) and Gross Margin (2020-2025)

Table 90. Biosynth Carbosynth Tocilizumab Product Offerings

Table 91. Biosynth Carbosynth Recent Development

Table 92. SimSon Pharma Company Information

Table 93. SimSon Pharma Introduction and Business Overview

Table 94. SimSon Pharma Tocilizumab Sales (Kg), Revenue (US$ Million), Price (K USD/Kg) and Gross Margin (2020-2025)

Table 95. SimSon Pharma Tocilizumab Product Offerings

Table 96. SimSon Pharma Recent Development

Table 97. BOC Sciences Company Information

Table 98. BOC Sciences Introduction and Business Overview

Table 99. BOC Sciences Tocilizumab Sales (Kg), Revenue (US$ Million), Price (K USD/Kg) and Gross Margin (2020-2025)

Table 100. BOC Sciences Tocilizumab Product Offerings

Table 101. BOC Sciences Recent Development

Table 102. Clearsynth Company Information

Table 103. Clearsynth Introduction and Business Overview

Table 104. Clearsynth Tocilizumab Sales (Kg), Revenue (US$ Million), Price (K USD/Kg) and Gross Margin (2020-2025)

Table 105. Clearsynth Tocilizumab Product Offerings

Table 106. Clearsynth Recent Development

Table 107. LifeSpan BioSciences Company Information

Table 108. LifeSpan BioSciences Introduction and Business Overview

Table 109. LifeSpan BioSciences Tocilizumab Sales (Kg), Revenue (US$ Million), Price (K USD/Kg) and Gross Margin (2020-2025)

Table 110. LifeSpan BioSciences Tocilizumab Product Offerings

Table 111. LifeSpan BioSciences Recent Development

Table 112. Key Raw Materials Lists

Table 113. Raw Materials Key Suppliers Lists

Table 114. Tocilizumab Downstream Customers

Table 115. Tocilizumab Distributors List

Table 116. Research Programs/Design for This Report

Table 117. Key Data Information from Secondary Sources

Table 118. Key Data Information from Primary Sources

List of Figures

Figure 1. Tocilizumab Product Picture

Figure 2. Global Tocilizumab Sales Value, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Global Tocilizumab Sales Value (2020-2031) & (US$ Million)

Figure 4. Global Tocilizumab Sales Volume (2020-2031) & (Kg)

Figure 5. Global Tocilizumab Sales Price (2020-2031) & (K USD/Kg)

Figure 6. Tocilizumab Report Years Considered

Figure 7. Global Tocilizumab Players Revenue Ranking (2024) & (US$ Million)

Figure 8. Global Tocilizumab Players Sales Volume Ranking (2024) & (Kg)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Tocilizumab Revenue in 2024

Figure 10. Tocilizumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 11. Min Purity Less Than 98% Picture

Figure 12. Min Purity 98%-99% Picture

Figure 13. Min Purity More Than 99% Picture

Figure 14. Global Tocilizumab Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)

Figure 15. Global Tocilizumab Sales Value Market Share by Type, 2024 & 2031

Figure 16. Global Tocilizumab Sales Volume by Type (2020 VS 2024 VS 2031) & (Kg)

Figure 17. Global Tocilizumab Sales Volume Market Share by Type, 2024 & 2031

Figure 18. Global Tocilizumab Price by Type (2020-2031) & (K USD/Kg)

Figure 19. Product Picture of Research

Figure 20. Product Picture of Medical

Figure 21. Global Tocilizumab Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)

Figure 22. Global Tocilizumab Sales Value Market Share by Application, 2024 & 2031

Figure 23. Global Tocilizumab Sales Volume by Application (2020 VS 2024 VS 2031) & (Kg)

Figure 24. Global Tocilizumab Sales Volume Market Share by Application, 2024 & 2031

Figure 25. Global Tocilizumab Price by Application (2020-2031) & (K USD/Kg)

Figure 26. North America Tocilizumab Sales Value (2020-2031) & (US$ Million)

Figure 27. North America Tocilizumab Sales Value by Country (%), 2024 VS 2031

Figure 28. Europe Tocilizumab Sales Value, (2020-2031) & (US$ Million)

Figure 29. Europe Tocilizumab Sales Value by Country (%), 2024 VS 2031

Figure 30. Asia Pacific Tocilizumab Sales Value, (2020-2031) & (US$ Million)

Figure 31. Asia Pacific Tocilizumab Sales Value by Region (%), 2024 VS 2031

Figure 32. South America Tocilizumab Sales Value, (2020-2031) & (US$ Million)

Figure 33. South America Tocilizumab Sales Value by Country (%), 2024 VS 2031

Figure 34. Middle East & Africa Tocilizumab Sales Value, (2020-2031) & (US$ Million)

Figure 35. Middle East & Africa Tocilizumab Sales Value by Country (%), 2024 VS 2031

Figure 36. Key Countries/Regions Tocilizumab Sales Value (%), (2020-2031)

Figure 37. Key Countries/Regions Tocilizumab Sales Volume (%), (2020-2031)

Figure 38. United States Tocilizumab Sales Value, (2020-2031) & (US$ Million)

Figure 39. United States Tocilizumab Sales Value by Type (%), 2024 VS 2031

Figure 40. United States Tocilizumab Sales Value by Application (%), 2024 VS 2031

Figure 41. Europe Tocilizumab Sales Value, (2020-2031) & (US$ Million)

Figure 42. Europe Tocilizumab Sales Value by Type (%), 2024 VS 2031

Figure 43. Europe Tocilizumab Sales Value by Application (%), 2024 VS 2031

Figure 44. China Tocilizumab Sales Value, (2020-2031) & (US$ Million)

Figure 45. China Tocilizumab Sales Value by Type (%), 2024 VS 2031

Figure 46. China Tocilizumab Sales Value by Application (%), 2024 VS 2031

Figure 47. Japan Tocilizumab Sales Value, (2020-2031) & (US$ Million)

Figure 48. Japan Tocilizumab Sales Value by Type (%), 2024 VS 2031

Figure 49. Japan Tocilizumab Sales Value by Application (%), 2024 VS 2031

Figure 50. South Korea Tocilizumab Sales Value, (2020-2031) & (US$ Million)

Figure 51. South Korea Tocilizumab Sales Value by Type (%), 2024 VS 2031

Figure 52. South Korea Tocilizumab Sales Value by Application (%), 2024 VS 2031

Figure 53. Southeast Asia Tocilizumab Sales Value, (2020-2031) & (US$ Million)

Figure 54. Southeast Asia Tocilizumab Sales Value by Type (%), 2024 VS 2031

Figure 55. Southeast Asia Tocilizumab Sales Value by Application (%), 2024 VS 2031

Figure 56. India Tocilizumab Sales Value, (2020-2031) & (US$ Million)

Figure 57. India Tocilizumab Sales Value by Type (%), 2024 VS 2031

Figure 58. India Tocilizumab Sales Value by Application (%), 2024 VS 2031

Figure 59. Tocilizumab Industrial Chain

Figure 60. Tocilizumab Manufacturing Cost Structure

Figure 61. Channels of Distribution (Direct Sales, and Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Tocilizumab market? zhanKai

The top companies in the global Tocilizumab market are Bio-Rad Laboratories、Bio-Techne、BioVision.

Related Reports

Tocilizumab- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Tocilizumab was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-07-14
Pages: 140
USD 3950.00
(Single User License)
Global Tocilizumab Market Research Report 2026
The global Tocilizumab market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-04-21
Pages: 143
USD 2900.00
(Single User License)
Global Tocilizumab Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Tocilizumab market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-10-22
Pages: 152
USD 4900.00
(Single User License)
Global Tocilizumab Market Research Report 2025
The global market for Tocilizumab was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-02-15
Pages: 99
USD 2900.00
(Single User License)
Global Tocilizumab Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Tocilizumab market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-15
Pages: 93
USD 4250.00
(Single User License)
Global Tocilizumab Market Insights, Forecast to 2030
Tocilizumab is a humanized monoclonal antibody resistant against the interleukin-6 receptor (IL-6R). It is an immunosuppressive agent commonly used for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis.
Published Date: 2024-04-07
Pages: 105
USD 4900.00
(Single User License)
Tocilizumab - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Tocilizumab is a humanized monoclonal antibody resistant against the interleukin-6 receptor (IL-6R). It is an immunosuppressive agent commonly used for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis.
Published Date: 2024-02-19
Pages: 121
USD 3950.00
(Single User License)
Global Tocilizumab Market Research Report 2024
Tocilizumab is a humanized monoclonal antibody resistant against the interleukin-6 receptor (IL-6R). It is an immunosuppressive agent commonly used for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis.
Published Date: 2024-01-12
Pages: 102
USD 2900.00
(Single User License)

Tocilizumab- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Tocilizumab was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-07-14
Pages: 140
USD 3950.00 (Single User License)
Global Tocilizumab Market Research Report 2026
The global Tocilizumab market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-04-21
Pages: 143
USD 2900.00 (Single User License)
Global Tocilizumab Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Tocilizumab market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-10-22
Pages: 152
USD 4900.00 (Single User License)
Global Tocilizumab Market Research Report 2025
The global market for Tocilizumab was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-02-15
Pages: 99
USD 2900.00 (Single User License)
Global Tocilizumab Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Tocilizumab market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-15
Pages: 93
USD 4250.00 (Single User License)
Global Tocilizumab Market Insights, Forecast to 2030
Tocilizumab is a humanized monoclonal antibody resistant against the interleukin-6 receptor (IL-6R). It is an immunosuppressive agent commonly used for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis.
Published: 2024-04-07
Pages: 105
USD 4900.00 (Single User License)
Tocilizumab - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Tocilizumab is a humanized monoclonal antibody resistant against the interleukin-6 receptor (IL-6R). It is an immunosuppressive agent commonly used for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis.
Published: 2024-02-19
Pages: 121
USD 3950.00 (Single User License)
Global Tocilizumab Market Research Report 2024
Tocilizumab is a humanized monoclonal antibody resistant against the interleukin-6 receptor (IL-6R). It is an immunosuppressive agent commonly used for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis.
Published: 2024-01-12
Pages: 102
USD 2900.00 (Single User License)